title: [Examination of the safety of docetaxel/cyclophosphamide combination therapy for advanced recurrent breast cancer].
abstract: In the treatment of recurrent breast cancer in patients previously treated with anthracycline drugs, taxane drugs are generally used. This time, we retrospectively studied the safety of docetaxel/cyclophosphamide combination therapy (hereinafter referred to as TC therapy). Ten patients (mean age: 52.8 years old) were included in the study. Metastatic/recurrent sites included 3 skin, 2 each of contralateral breast, lung and bone, and 1 each of liver, carcinomatous pleurisy and supraclavicular lymph node. Seven patients had a history of anthracycline treatment. The patients received TC at doses of 60 mg/m(2) and 500 mg/m(2), respectively, every 3 weeks. With regard to adverse events, non-hematotoxic events included alopecia in all the patients, generalized malaise in 5, and abnormal nail in 1. Hematotoxic events were grades 2 and 3 decreased neutrophil count in 5 patients. One patient had grade 4 pyrexia associated with oral candida. The patient was admitted and treated with fluid replacement and granulocyte colony-stimulating factor (G-CSF). There were no other patients in whom the treatment was prolonged or dosage was reduced due to adverse reactions. TC therapy is considered to be a beneficial treatment method in terms of safety since it can be instituted on an outpatient basis.
authors.affiliation: Dept. of Surgery, Saiseikai Central Hospital.
authors.forename: Kimiyasu
authors.initials: K
authors.lastname: Yoneyama
authors.forename: Yoshitomo
authors.initials: Y
authors.lastname: Koshida
authors.forename: Fumiki
authors.initials: F
authors.lastname: Toriumi
authors.forename: Takaya
authors.initials: T
authors.lastname: Murayama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Toeda
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Imazu
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Motegi
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Akamatsu
authors.forename: Renpei
authors.initials: R
authors.lastname: Ohyama
mesh_terms: D000328:Adult; D000505:Alopecia / Q000139:chemically induced; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000556:secondary; D013280:Stomatitis / Q000139:chemically induced; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D003520:Cyclophosphamide